1. Home
  2. HCWB vs AIDX Comparison

HCWB vs AIDX Comparison

Compare HCWB & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HCW Biologics Inc.

HCWB

HCW Biologics Inc.

SELL

Current Price

$0.99

Market Cap

3.6M

Sector

Health Care

ML Signal

SELL

Logo 20/20 Biolabs Inc. Common Stock

AIDX

20/20 Biolabs Inc. Common Stock

HOLD

Current Price

$0.21

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HCWB
AIDX
Founded
2018
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Precision Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6M
2.9M
IPO Year
2021
2025

Fundamental Metrics

Financial Performance
Metric
HCWB
AIDX
Price
$0.99
$0.21
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
82.2K
★ 208.0K
Earning Date
11-24-2026
11-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 34.48
EPS
N/A
★ N/A
Revenue
★ $4,099,750.00
$2,045,133.00
Revenue This Year
$12,215.61
$44.20
Revenue Next Year
N/A
$95.73
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 16.71
52 Week Low
$0.86
$0.18
52 Week High
$23.94
$18.96

Technical Indicators

Market Signals
Indicator
HCWB
AIDX
Relative Strength Index (RSI) 29.59 33.51
Support Level $0.86 N/A
Resistance Level $1.28 $0.27
Average True Range (ATR) 0.09 0.03
MACD 0.02 0.00
Stochastic Oscillator 18.49 34.53

Price Performance

Historical Comparison
HCWB
AIDX

About HCWB HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

About AIDX 20/20 Biolabs Inc. Common Stock

20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.

Share on Social Networks: